Published on 03/12/2025

Data Drift from New Markets/Sites

In the rapidly advancing field of pharmaceuticals, the application of AI and machine learning (ML) models has become increasingly prevalent. However, navigating the complexities associated with data drift when using these models is essential to maintain compliance with Good Automated Manufacturing Practice (GxP) regulations. This step-by-step tutorial focuses on critical aspects of AI/ML model validation in laboratories, with a particular emphasis on the challenges posed by incorporating new markets or sites. It discusses how to handle intended use risk, as well as best practices for data readiness curation, ensuring a robust validation process in compliance with regulatory requirements.

Understanding Data Drift in AI/ML Models

Data drift refers to the changes in the statistical properties of models over time, which can lead to shifts in their performance. This phenomenon poses a significant concern in pharmaceuticals, where statistical accuracy can directly impact patient safety and product efficacy. When a model is first validated for a specific set of data characteristics, introducing new sites or markets can result in unexpected variations. This necessitates a thorough analysis of how these changes might affect the model’s predictive capabilities.

Data drift can manifest in several ways, including:

• Covariate Shift: The distribution of input data changes, while the relationship between input and output remains unchanged.
• Prior Probability Shift: The output distribution changes, possibly affecting the overall prediction accuracy.
• Concept Drift: The underlying relationship between input and output changes over time.

To identify these drifts, continuous monitoring must be implemented. Best practices suggest utilizing statistical tools to establish drift detection thresholds tailored to the specific requirements of laboratory environments.

Intended Use Risk and Data Readiness Curation

A critical first step in AI/ML model validation in laboratories is clearly defining the intended use of the model. Regulatory bodies such as the FDA expect that model outputs align with their intended application. Hence, it is essential to detail every facet of the model—its purpose, target population, and the decision-making process it will influence.

Once the intended use is established, laboratory professionals must assess data readiness. This involves curating and preprocessing the data to ensure that it meets the predefined standards for accuracy, completeness, and relevance. Factors to consider include:

• Assessing data lineage to confirm that data sources are reliable and continuously monitored.
• Implementing strategies for data cleaning to remove any inconsistencies that may introduce bias.
• Collecting representative samples from both existing and new sites, critically analyzing the potential influences of geographical and demographic diversity.

Effective data readiness can alleviate the risks associated with improper model usage and significantly improve the overall outcome of AI/ML applications in labs.

Bias and Fairness Testing in AI/ML Models

As AI and ML models become integrated into more complex laboratory processes, ensuring that they are both fair and unbiased has emerged as a priority. Bias can be introduced at multiple points, including the data collection phase or through the algorithmic structure. Regulatory entities and stakeholders demand rigour in monitoring, especially as these technologies influence patient outcomes.

To conduct bias and fairness testing, laboratory professionals should:

• Identify Potential Sources of Bias: Examine data sources and demographic variables that could lead to skewed results.
• Evaluate Model Outputs: Analyze outputs across different sub-groups to ensure that predictions are equitable.
• Incorporate Fairness Metrics: Employ statistical fairness measures to assess the model’s performance across diverse populations.

Regularly validating and retesting models for bias, especially after introducing data from new markets or sites, will fortify adherence to ethical standards and regulatory compliance.

Model Verification and Validation Processes

Model verification and validation (V&V) are integral to the regulatory approval process for AI/ML applications in laboratories. V&V ensures that models perform as intended and are suitable for their predefined uses within the clinical and operational contexts.

To establish a comprehensive model V&V framework, follow these structured steps:

• Define Performance Criteria: Establish clear performance metrics based on the model’s intended use and the regulatory requirements.
• Conduct Verification: Through rigorous testing, verify that the model meets its specifications during the development phase. This includes ensuring that outputs are reproducible and consistent.
• Execute Validation: Validate the model using a representative data set, simulating real-world conditions. Collect feedback through clinical outcome measures and ensure alignment with intended use.

Adhering to regulatory guidelines including GAMP 5, which outlines a risk-based approach for software validation, will enhance the credibility of model V&V processes, ensuring they are compliant with standards like EMA guidelines.

Drift Monitoring & Re-Validation Strategies

Continuous monitoring for data drift is paramount to the success of AI/ML applications in GxP-regulated environments. Implementing robust strategies for drift detection and re-validation can mitigate risks associated with performance degradation due to changing data patterns.

Here are critical elements to integrate into your drift monitoring framework:

• Establish Baseline Performance Metrics: Develop baseline metrics derived from the original validation datasets, using these benchmarks for future comparisons.
• Implement Continuous Surveillance: Utilize statistical tests to continuously assess model performance against these baseline measurements. Techniques may include the Kolmogorov-Smirnov test or techniques from data stream mining.
• Plan for Re-Validation: After detecting drift, establish a clear re-validation strategy, correlating adjustments or model retraining with defined triggers that align with operational updates or new market integrations.

Documentation of the entire monitoring process should be meticulously maintained, establishing a trail that can be audited to confirm compliance with 21 CFR Part 11 regulations regarding electronic records and signatures.

Documentation & Audit Trails in AI/ML Model Validation

Comprehensive documentation is a hallmark of quality assurance in pharmaceuticals, particularly for AI/ML validation processes. Regulatory agencies, such as the WHO, require transparency in documentation to clarify the decision-making process surrounding model performance, biases, and testing methodologies.

Key elements of documentation for AI/ML validation include:

• Validation Protocols: Clearly outline procedures for data readiness, model design, testing, and monitoring plans.
• Version Control: Maintain version control of model iterations, alongside data versions to explain what changes were made and why.
• Audit Logs: Create comprehensive audit trails that log all modifications, including model parameters and data adjustments. This should be in alignment with Annex 11 requirements for electronic records.

AI Governance & Security in Pharmaceutical Laboratories

As reliance on AI/ML technologies increases in laboratories, establishing a robust governance framework is crucial. AI governance encompasses defining accountability structures, data security measures, and ethical standards that ensure technologies function within compliance parameters.

To implement an effective governance framework, consider the following best practices:

• Define Governance Roles: Outline clear roles and responsibilities for stakeholders involved in model implementation, including compliance officers, technical teams, and quality assurance personnel.
• Establish Security Protocols: Ensure the implementation of security measures such as encryption, access controls, and data anonymization procedures to mitigate risks of data breaches.
• Facilitate Training Programs: Conduct regular training sessions to educate laboratory personnel on AI compliance, ethical use, and security best practices.

By prioritizing governance and security, laboratories can maximize the potential of AI/ML model applications while maintaining ethical standards and regulatory compliance.

Conclusion

Data drift from new markets or sites poses significant challenges for AI/ML model validation within the pharmaceutical industry. By adopting a thorough understanding of intended use and data readiness, conducting rigorous bias testing, and adhering to best practices in model verification and validation, laboratories can enhance model performance and regulatory compliance. Furthermore, implementing continuous drift monitoring and maintaining robust documentation ensures that models remain aligned with compliance standards. An overarching governance framework will solidify the positions of laboratories in this evolving technological landscape, allowing for optimized use of AI/ML technologies while prioritizing patient safety and product quality.